1. Generic & Brand Names
Generic: Levofloxacin
Brands: Levaquin® (discontinued in US), Tavanic® (EU), Iquix® (ophthalmic)
Formulations:
Tablets (250mg, 500mg, 750mg)
Oral solution (25mg/mL)
IV infusion (250mg/50mL, 500mg/100mL, 750mg/150mL)
2. Drug Class & Mechanism
Class: Fluoroquinolone antibiotic (3rd gen)
Mechanism: Inhibits DNA gyrase/topoisomerase IV → bactericidal
Spectrum:
Gram-positive: S. pneumoniae (including penicillin-resistant), S. aureus (MSSA)
Gram-negative: H. influenzae, M. catarrhalis, Enterobacteriaceae, P. aeruginosa
Atypicals: Legionella, Mycoplasma, Chlamydia
3. FDA-Approved Respiratory Uses
| Infection Type | Key Pathogens | Status |
|---|---|---|
| Community-Acquired Pneumonia (CAP) | S. pneumoniae, H. influenzae, M. pneumoniae | First-line for severe cases |
| Hospital-Acquired Pneumonia (HAP) | P. aeruginosa, MSSA | Reserved for MDR risk |
| Acute Bacterial Sinusitis | S. pneumoniae, H. influenzae | Last-resort only (after β-lactam failure) |
| Acute COPD Exacerbations | H. influenzae, M. catarrhalis | Restricted* |
⚠️ FDA BLACK BOX WARNINGS (2016):
Tendon rupture (Achilles > shoulder)
Peripheral neuropathy (irreversible)
CNS effects (seizures, psychosis)
Exacerbates myasthenia gravis
Avoid for uncomplicated infections (sinusitis/bronchitis/UTIs) unless no alternatives
4. Dosing Regimens
| Infection Type | Adult Dose | Duration |
|---|---|---|
| CAP (Outpatient) | 750 mg PO/IV daily | 5 days |
| CAP (Inpatient) | 750 mg IV daily → switch to PO | 7-14 days |
| HAP | 750 mg IV daily | 7-14 days |
| Acute Sinusitis | 500 mg PO/IV daily | 10-14 days (only if severe/recurrent) |
| Renal Adjustment: |
CrCl 20-49 mL/min: 750 mg → 500 mg
CrCl 10-19 mL/min: 750 mg → 250 mg
5. Critical Side Effects
| Common (≥5%) | Serious (Discontinue Immediately) |
|---|---|
| Nausea/vomiting | Tendon rupture (any age) |
| Diarrhea | QT prolongation → Torsades |
| Headache | Aortic aneurysm/dissection |
| Photosensitivity | Hypoglycemia (↓ glucose) |
| Insomnia | C. difficile colitis |
6. Drug Interactions
| Medication | Risk | Management |
|---|---|---|
| NSAIDs | ↑ Seizure risk | Avoid combo |
| Corticosteroids | ↑ Tendon rupture risk | Contraindicated |
| Antidiabetics | ↑ Hypoglycemia (risk persists 2 weeks) | Monitor glucose QID |
| QT-prolonging drugs | Amiodarone, antipsychotics | ECG monitoring required |
| Divalent cations | ↓ Absorption (Al³⁺, Mg²⁺, Ca²⁺) | Separate by 4-6 hours |
7. Resistance & Stewardship
S. pneumoniae Resistance: 15-25% in US (IDSA 2024)
When to Use:
Severe CAP with risk factors (alcoholism, COPD, aspiration)
Penicillin-allergic patients with HAP
Sinusitis failing amoxicillin-clavulanate
Avoid:
Mild CAP (use doxycycline)
Viral URIs
Pediatric patients (cartilage toxicity)
8. IV-to-PO Transition
Bioavailability: 99% → switch when clinically stable
IV Administration:
Infuse 750 mg over ≥90 minutes (rapid infusion → hypotension)
Max IV duration: 10 days (↑ thrombophlebitis risk)
9. Patient Counseling Essentials
"Stop drug and call MD immediately for:
Tendon/joint pain
Tingling/numbness in limbs
Mood changes/suicidal thoughts
Avoid:
Sun exposure (use SPF 50+)
Antacids/vitamins 4h before/after dose
Strenuous exercise
10. Storage & Handling
Tablets: 15-30°C (59-86°F); protect from moisture
Oral Solution: Discard after 14 days (room temp)
IV Solution: Discard unused portions; refrigerate vials
Clinical Practice Guidelines
| Scenario | Recommendation |
|---|---|
| Severe CAP | Levofloxacin 750mg + ceftriaxone |
| HAP with Pseudomonas risk | Levofloxacin + piperacillin-tazobactam |
| Recurrent sinusitis | Only after culture confirmation |
| Renal impairment | ↓ Dose + ECG monitoring |
Why Levofloxacin Is Restricted
Alternatives to Levofloxacin
| Infection | Preferred Agents |
|---|---|
| Mild CAP | Doxycycline, Amoxicillin |
| Sinusitis | Amoxicillin-clavulanate |
| HAP | Piperacillin-tazobactam, Cefepime |
💡 Key Insight: Reserve for life-threatening infections when benefits outweigh risks. Document justification in medical record per FDA.
Prescribing Status: Requires prior authorization in US/EU for non-approved indications. Report adverse events to FDA MedWatch.
Comments
Post a Comment